Adicet Bio
ACET
83 hedge funds and large institutions have $48.9M invested in Adicet Bio in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 30 increasing their positions, 22 reducing their positions, and 23 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 22
0.23% less ownership
Funds ownership: 5.41% → 5.18% (-0.23%)
12% less funds holding
Funds holding: 94 → 83 (-11)
43% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 23
46% less capital invested
Capital invested by funds: $90.4M → $48.9M (-$41.5M)
87% less call options, than puts
Call options by funds: $9K | Put options by funds: $70K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.07M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.1M |
| 3 |
Renaissance Technologies
New York
|
+$1.03M |
| 4 |
Two Sigma Advisers
New York
|
+$622K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$550K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$2.77M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.24M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.89M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$1.74M |
| 5 |
DCMIC
Decheng Capital Management III (Cayman)
Grand Cayman,
Cayman Islands
|
-$674K |
ACET Hedge Fund Activity: Q3 2023 in Review
83 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q3 2023, worth a combined $48.9M — down 46% from $90.4M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of ACET and 13 opened new positions — a net loss of 10 holders — while 22 trimmed existing stakes and 30 added.
The largest buyer was Morgan Stanley, adding an estimated $3.07M. The largest seller was Tang Capital Management, cutting an estimated $2.77M.
- 83 institutional investors held Adicet Bio (ACET) as of Q3 2023, down from 94 in Q2 2023.
- Funds reported $48.9M of Adicet Bio stock for Q3 2023, down 46% quarter-over-quarter.
- 13 funds opened new Adicet Bio positions in Q3 2023 and 23 closed out, a net change of -10 holders.
- The largest Adicet Bio buyer in Q3 2023 was Morgan Stanley, an estimated $3.07M added.
- The largest Adicet Bio seller in Q3 2023 was Tang Capital Management, an estimated $2.77M sold.
Based on aggregated 13F filings for Q3 2023.